# BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)

> **NCT02047110** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 159 (actual)

## Conditions studied

- Ankylosing Spondylitis (AS)

## Interventions

- **DRUG:** placebo for risankizumab
- **DRUG:** risankizumab

## Key facts

- **NCT ID:** NCT02047110
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-28
- **Primary completion:** 2015-03-05
- **Final completion:** 2016-07-25
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2019-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02047110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02047110, "BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02047110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*